The ARO invites proposals for funding of small grants (up to $1000) to support activities either in the US or internationally that would enhance our mission and visibility as the premier hearing research organization in the world. Some specific activities that could be considered include:
- Sponsorship of an invited lecture for an ARO-member at a meeting, either national or international, particularly one at which ARO does not typically have a presence.
- Partial support of small 'local' research meetings that serve as a venue for members to meet to discuss focused topics; student participation may be targeted in these grants.
- Partial support of symposium at an international meeting, for presentations by ARO members, on a topic of interest to members of that society and attendees of the meeting.
Requirements: Applicants must be ARO members, and lectures/events must include a slide and/or other materials that acknowledge ARO support. The ARO will fund up to three grants per year.
Please send proposals to ARO headquarters at firstname.lastname@example.org
Please see funding opportunities that have been submitted to the ARO by likeminded organizations. If you would like your funding opportunity posted to the ARO website, please email the details to email@example.com
Department of Defense Hearing Center of Excellence (HCE)
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIDCD would like to share two new funding opportunities related to HIV/AIDS:
The purpose of these Funding Opportunity Announcements (FOA) are to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, and language.
American Hearing Research Foundation
Starting in 2022, the American Hearing Research Foundation is streamlining its grant offerings. Researchers may apply for the following grants:
- Discovery Grants – five to six awards of up to $50,000 each – for research related to hearing, or hearing and balance disorders of the inner ear.
Two topics continue to be of special interest for AHRF funding: the causes of sudden hearing loss, and Meniere’s disease. Proposals addressing these topics will receive special consideration during the review process.
If a particularly promising study is identified, AHRF may award one $75,000 Birtman Grant for exceptional scientific investigation. In this case, the recipient will be asked to provide updated aims and budget.
- Resident Grants – up to five $1,000 grants for otolaryngology residents at Chicago universities, or Washington University, St. Louis, Missouri; University of Miami, Florida; Baylor College of Medicine, Houston, Texas.
For more information, visit https://www.american-hearing.org/research-grants/grants-we-offer/ or contact us at firstname.lastname@example.org.
Deadline: August 16, 2021
Usher Syndrome Society Request for Applications Translational Research Grant
Letter of Intent Due: August 27, 2021
Applications Due: October 15, 2021
Notification of Award: December 1, 2021
Funds Available: January 1, 2022
Please submit grant materials as a single PDF file to email@example.com
For questions regarding these instructions, please contact the USS firstname.lastname@example.org
Background: The Usher Syndrome Society (USS) is a non-profit organization that uses the arts, educational events, and collaboration to raise awareness and funding for Usher syndrome (USH) research. USS funds research designed to develop treatments and cures for all forms of Usher syndrome. USS has secured commitments for $500,000 to fund USH research. For more information see: https://www.ushersyndromesociety.org/welcome.html
To fulfill the goal of “timely and efficient translation”, USS Translational Research Grants are intended to support translation al research on Usher syndrome within the domains of:
- Preclinical Research, encompassing basic science research with a direct link to the clinical population (human genetics, patient tissue, iPSC, humanized animal models).
- Mechanism-based Therapeutic Development, focused on novel disease modifying therapeutic modalities utilizing in vitro or in vivo preclinical models.
- Purpose of grants: Proposed research projects must be related to the mission of the USS. The USS focus is on the discovery pipeline including identification of therapeutic strategies and development of novel therapeutic agents. Particular emphasis is placed on collaborative efforts that extend across sensory modalities and platform technologies that may advance therapeutic development for multiple forms of USH. Proposals that address specific mutations, such as USH2A exon 20 mutations, are also encouraged.
- Description of grants:
- New research proposals: These grants are up to two years of support, contingent upon adequate progress. The maximum allowable budget (direct costs only, no indirect costs allowed) is $100,000 per year. The number of awardees will be determined by the quality of the proposals, the total amount of the requested budgets of sufficiently meritorious proposals, and available funds. It is anticipated that 2-3 awards will be made. The second year of funding will be based on adequate progress and milestone achievements and will be reviewed on a non-competitive basis.
- Research projects that include well-documented collaborations that merge research efforts across sensory modalities and across scientific disciplines will be prioritized. Further priority will be assigned to applications that may offer the greatest benefit for the largest patient population or targeted approaches that hold great promise for select mutations, such as those found in USH2A exon 20.
- Principle investigators selected for funding will have collaborative consultations biyearly with USS scientific advisors for feedback and progress updates.
- Eligibility: Applications will be accepted from research scientists at qualified U.S. and international research institutions. Collaborative projects between U.S. and international scientists are also acceptable. Applicant principle investigators must hold a tenure-track faculty position with an M.D., Ph.D., M.D.-Ph.D., or equivalent degree.
- LOI: The initial Letter of Intent (LOI) will have a 1-page limit. The LOI should include USH gene(s) of interest, a hypothesis, specific aims and a brief description of the research design and methods. LOIs will be screened to determine if the proposed research project is consistent with the goals of the USS. Following screening, notifications will be sent to selected investigators inviting submission of a full application. LOIs must be submitted to email@example.com by 5 pm on August 27, 2021. An email confirmation of receipt will be returned to the applicant. Invitations to submit a full application will be sent by Sept 3, 2021.
- Full applications (invited following review of LOI): Full applications must be submitted in single-spaced text, one-half inch margins, and 12-point Arial or Helvetica font. The primary applicant’s name must appear in the upper right-hand corner of each page. Proposal text is limited to five pages (including figures, excluding references). Use standard PHS 398 forms for biosketch and other support.
- Application submission: Submit applications electronically as a single PDF file to firstname.lastname@example.org by 5 pm on October 15, 2021.
- Composition of research proposal: Invited research proposals should include:
- Cover Letter
- Abstracts, scientific (250 words) and lay summary (100 words)
- Budget & Budget Justification (1 page limit)
- Biosketch(es) (include PI and co-investigators; NIH format)
- Other support page (list pending and current support only)
- Research Plan (5 page limit, not including references)
- Hypothesis and Specific Aims
- Background and Significance
- Preliminary Results
- Research Design and Methods
- Statement of how proposal supports USS mission and research priorities
- Literature cited
- *Letters of support from collaborators or consultants (1 page limit/letter) *optional
- Grant review: Applications will be reviewed and prioritized for funding by a multidisciplinary scientific advisory committee composed of established hearing/vision scientists. The committee will be chaired by Jeffrey R. Holt, Ph.D., Professor of Otolaryngology and Neurology at Boston Children’s Hospital and Harvard Medical School.
Medicines Discovery Catapult and We Share Ventures
We are delighted to announce a new partnership between Medicines Discovery Catapult and We Share Ventures. The partnership brings together We Share’s innovative impact-driven revolving funding model with MDC Syndicate’s programme, enabling promising start-ups in the medicine discovery space access to long-term capital in the early phases of their growth. We Share’s innovative philanthropic approach is underpinned by a share-it-forward principle, where grants are raised via philanthropic donations and awarded to start-ups with favourable conditions - a long-term repayment, based on success milestones. This, in turn, creates a revolving funding pool to support a new generation of impact-driven start-ups.
This autumn, we will hold a call for applications for start-ups across Europe with preclinical-stage medicines discovery projects aiming to address patient need in areas aligned to our Syndicate portfolio: cystic fibrosis-related infections, hearing loss and tinnitus and psychiatric disorders. Full details and terms and conditions will be announced soon.
You can find out more about the partnership by reading our press release.
For further information, interested parties should contact email@example.com